Dr Alison Reynolds wins inaugural UCD Allergan Innovation AwardMonday, 02 October, 2017
Dr Alison Reynolds.
Dr Alison Reynolds has won the inaugural University College Dublin (UCD) Allergan Innovation Award in recognition of the innovative potential within her research to develop a new therapy for dry eye disease.
2017 UCD Allergan Innovation awardee, Dr Alison ReynoldsDr Reynolds is an early career researcher in the UCD School of Veterinary Medicine with close ties to the ocular pharmacology and genetics group based in the UCD Conway Institute. This award will provide Dr Reynolds with a research bursary of €7,000 to enable her to develop a novel compound, uncovered in zebrafish, as a dry eye disease therapeutic.
Tears lubricate the front of the eyes and allow us to blink without discomfort. Dry eye disease causes discomfort for up to 30% of people age 65 or older in Ireland each year. Eyes feel irritated, sore and appear red, due to the combined effects of chronic inflammation and the reduced quality of tears that can lead to corneal damage. At present, treatment options for dry eye disease can be of limited benefit to the patient. Dr Reynolds believes that the new compound identified, using tiny tropical fish as a research model, may provide a better alternative for the treatment of dry eye disease.
Speaking today Allergan Innovation Award winner at UCD, Dr Reynolds said: “The bursary will make a real difference to my research, enabling me to carry out pilot efficacy studies, visit international ocular surface experts and attend the Ophthalmology Futures Forum meeting in 2018. I am very grateful to Allergan for this opportunity. I would also like to thank Enterprise Ireland for funding this work and my UCD colleagues for their contributions and support.”
Speaking at the award ceremony, Professor William Gallagher, Director, UCD Conway Institute and Professor of Cancer Biology in UCD School of Biomolecular & Biomedical Science said:
”A critical element within our mission is to place innovation to the forefront of our efforts, ensuring rapid and effective implementation of new findings for commercial and societal benefit.
“We are proud to train future scientific leaders and enable them for success in careers within industry, academia and research support agencies. We are delighted to engage with industry partners, such as Allergan plc. to explore the potential in developing fundamental research into commercial and clinical reality.”
In March 2017, Allergan marked 40 successful years of business in Ireland by announcing details of a new Innovation Award Programme. University College Dublin is one of six Higher Education Institutions around Ireland that Allergan is partnering with to provide funding to accomplished scholars, who wish to advance their innovative research studies in the field of life sciences. Dr Francis Bates, Vice President Global Solid Oral Dosage Manufacturing at Allergan, and the Plant General Manager at the manufacturing facility at Clonshaugh in Dublin presented the inaugural Allergan Innovation Award to Dr Alison Reynolds, at a ceremony during the 2017 UCD Conway Festival of Research & Innovation.
Announcing the winner, Francis Bates said:
“We are delighted to be partnering with University College Dublin for this year’s Allergan Innovation Award. To mark 40 successful years of business in Ireland, we wanted to build on our longstanding relationships with communities through providing educational support to universities and colleges around the country, by reaffirming our commitment to the future of Life Sciences. Our warmest congratulations to Dr Reynolds and we wish Dr Reynolds continued success with her research treatments for dry eye disease, a key therapeutic area for the Company.
We hope that this Innovation Award will inspire more students who wish to establish themselves within the field of Life Sciences. Collaborating with a prestigious university, such as University College Dublin, is an exciting initiative for all involved, and we look forward to the positive results and experiences it will bring for students and for our industry.”
A second bursary prize of €1,000 was presented to Dr Simon Rowan, a postdoctoral researcher working with Professor Paul McLoughlin, UCD School of Medicine and UCD Conway Institute. Dr Rowan’s research aims to exploit a new technique to recondition organs and maintain them for a longer period outside the body prior to transplant.
Pictured L-R: Francis Bates, GM, Allergan-Clonshaugh; Dr Alison Reynolds, Dr Simon Rowan, Professor William Gallagher, Director, UCD Conway Institute.
About Allergan plc
Allergan plc (www.Allergan.com), headquartered in Dublin, Ireland, is a global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercialising branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines their approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programmes in development.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live healthier lives every day.